Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Management
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Latest news

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • News

Study Finds That Masimo PVi Capable Of Predicting Fluid Responsiveness in Young Children Undergoing Neurosurgery

By Benzinga Newsdesk
Today, 10:00 PM
Masimo (NASDAQ:MASI) today announced the findings of a prospective study published in Pediatrics International in which Dr. Ya-Fei Liu and colleagues at Peking University First Hospital in Beijing

MASI

Read More
4 minute read
  • Biotech
  • General
  • News

New Study Evaluates The Use Of Masimo PVi As An Indicator Of Fluid Responsiveness To Guide Goal-Directed Fluid Therapy In Adult Neurosurgical Patients

By Happy Mohamed
Today, 10:00 PM
Researchers Found That Noninvasive, Continuous PVi Was Equally Effective in Guiding Fluid Management As Stroke Volume Variation (SVV), an Invasive Method Requiring an Arterial Line Masimo (NASDAQ:MASI) today

MASI

Read More
1 minute read
  • General
  • Health Care
  • Large Cap
  • Legal
  • News

$300B California Teachers Pension Fund Joins Politan Capital In Legal Action Against Masimo CEO’s Employment Agreement

By Vandana Singh
Today, 10:00 PM
The California State Teachers’ Retirement System (CalSTRS) has joined Politan Capital Management to stop Masimo Corp’s (NASDAQ:MASI) CEO from receiving…

MASI

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

Needham Maintains Buy on Masimo, Raises Price Target to $192

By Benzinga Newsdesk
Today, 10:00 PM
Needham analyst Mike Matson maintains Masimo (NASDAQ:MASI) with a Buy and raises the price target from $173 to $192.

MASI

Read More
1 minute read
  • Analyst Color
  • Analyst Ratings
  • General
  • Health Care
  • Movers
  • News
  • Price Target
  • Trading Ideas
  • Upgrades

Analyst Says This MedTech Giant Stock Offers ‘Too Much Optionality,’ Upgrades Rating

By Vandana Singh
Today, 10:00 PM
Raymond James upgraded Masimo Corporation (NASDAQ:MASI) from Market Perform To Outperform with a price target of $187 and says that no other company…

AAPL

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target
  • Upgrades

Raymond James Upgrades Masimo to Outperform, Announces $187 Price Target

By Benzinga Newsdesk
Today, 10:00 PM
Raymond James analyst Jayson Bedford upgrades Masimo (NASDAQ:MASI) from Market Perform to Outperform and announces $187 price target.

MASI

Read More
1 minute read
  • Legal
  • News

Masimo Wins IPR Patent Trial Vs Apple

By Benzinga Newsdesk
Today, 10:00 PM
https://ptacts.uspto.gov/ptacts/public-informations/petitions/1550005/download-documents?artifactId=170370051

AAPL

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

Stifel Maintains Buy on Masimo, Raises Price Target to $170

By Benzinga Newsdesk
Today, 10:00 PM
Stifel analyst Rick Wise maintains Masimo (NASDAQ:MASI) with a Buy and raises the price target from $164 to $170.

MASI

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target
  • Reiteration

Needham Reiterates Buy on Masimo, Maintains $173 Price Target

By Benzinga Newsdesk
Today, 10:00 PM
Needham analyst Mike Matson reiterates Masimo (NASDAQ:MASI) with a Buy and maintains $173 price target.

MASI

Read More
1 minute read
  • Legal
  • News

Reported Late Tuesday, ITC Judge Rules Apple Violated U.S. Trade Laws By Infringing Masimo Pulse Oximeter Patent

By Benzinga Newsdesk
Today, 10:00 PM
A United States Administrative Law Judge in Washington, D.C. ruled that Apple Inc. (NASDAQ:AAPL) violated Section 337 of the Tariff Act of 1930 as amended, by importing and selling within the United States certain Apple

AAPL

Posts navigation

1 2 … 7 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service